Huggins and Hodges 1 were the first to report that a sizeable proportion of men with advanced prostatic carcinoma responded satisfactorily to endocrine manipulation. Their findings were corroborated in several large-scale clinical trials. 2 , 3 Since then, additive and/or ablative hormonal therapies have been prime weapons in the treatment of metastatic prostatic malignancy.